Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInventory AverageInvested CapitalMarket Capitalization

RedHill Biopharma (RDHL) Debt to Equity: 2010-2023

Historic Debt to Equity for RedHill Biopharma (RDHL) over the last 14 years, with Dec 2023 value amounting to -$14.4 million.

  • RedHill Biopharma's Debt to Equity fell 125.27% to -$2.38 in Q4 2022 from the same period last year, while for Dec 2022 it was -$2.38, marking a year-over-year decrease of 125.27%. This contributed to the annual value of -$14.4 million for FY2023, which is 603949698.64% down from last year.
  • According to the latest figures from FY2023, RedHill Biopharma's Debt to Equity is -$14.4 million, which was down 603,949,698.64% from -$2.38 recorded in FY2022.
  • RedHill Biopharma's 5-year Debt to Equity high stood at $9.42 for FY2021, and its period low was -$14.4 million during FY2023.
  • Over the past 3 years, RedHill Biopharma's median Debt to Equity value was -$2.38 (recorded in 2022), while the average stood at -$4.8 million.
  • As far as peak fluctuations go, RedHill Biopharma's Debt to Equity surged by 4,093.08% in 2020, and later slumped by 603,949,698.64% in 2023.
  • Yearly analysis of 5 years shows RedHill Biopharma's Debt to Equity stood at $0.14 in 2019, then skyrocketed by 4,093.08% to $5.87 in 2020, then skyrocketed by 60.50% to $9.42 in 2021, then plummeted by 125.27% to -$2.38 in 2022, then tumbled by 603,949,698.64% to -$14.4 million in 2023.